Psoriatic Arthritis (PsA) research hub
5 indexed studies · 2 currently recruiting
- recruitingNA
Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
This study looks at how weight loss (using a medication called tirzepatide) or treatment with iksekizumab affects people with psoriatic arthritis who are also overweight or obese. It checks changes in their skin, joints, and fat.
United Kingdom - active not recruitingPHASE3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
This study is testing a new medicine, risankizumab, for adults with active psoriatic arthritis, especially those who haven't responded well to other treatments. It aims to see how safe and effective it is in reducing symptoms.
United States · Argentina · Australia - recruiting
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
This study looks at how well certain new treatments work for people with types of arthritis called axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). It gathers information from medical records and patient surveys to understand treatment effectiveness from different viewpoints.
United Kingdom - authorisedTherapeutic confirmatory (Phase III)
Clinical and ultrasound assessment of the therapeutic response to ixekizumab in psoriatic arthritis dactlylitis; a multicentre, parallel-groups, randomised controlled trial
This study looks at how well a medicine called Taltz (ixekizumab) works for adults with a type of arthritis called psoriatic arthritis, specifically when it affects fingers and toes. We're comparing it to another medication, Metoject (methotrexate), to see which one helps more with swelling and pain.
Italy - authorisedTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
This study looks at a new medicine called sonelokimab for psoriatic arthritis. It checks how safe and helpful the medicine is over a long time for people who have already tried it in another study. Doctors will monitor side effects and overall health.
Estonia · Croatia · Slovakia